CompanyNMADNasdaqBoca Raton, FL

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology is a clinical-stage biopharmaceutical company developing LB-100, a protein phosphatase 2A inhibitor for cancer, in trials for ovarian clear cell carcinoma and metastatic colon cancer.

Stories only

SEC EDGAR ClinicalTrials.gov ir.nomadpower.com

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Nomad Power Solutions raises $6.0 million via secured note, with Lixte as guarantor subsidiary

Sep 30FinancingLixte Biotechnology Holdings, Inc.

July 2026

Lixte Biotechnology completes merger with Nomad, becomes Nomad Power Solutions

Jul 2M&ALixte Biotechnology Holdings, Inc.